Stock BLISSGVS BLISS GVS PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bliss GVS Pharma Limited NSE India S.E.

Equities

BLISSGVS

INE416D01022

Pharmaceuticals

Delayed NSE India S.E.
Other stock markets
 06:28:33 2024-05-03 am EDT 		5-day change 1st Jan Change
119 INR -8.00% Intraday chart for Bliss GVS Pharma Limited +4.38% -4.49%
May. 02 Bliss GVS Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
May. 02 Bliss GVS Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 20,150 18,561 10,397 10,181 7,978 7,421
Enterprise Value (EV) 1 20,785 18,712 11,261 10,783 7,723 7,756
P/E ratio 34.3 x 15 x 10.7 x 15.2 x 53.8 x 10.6 x
Yield 0.51% 0.56% 0.5% 0.51% 0.65% 0.7%
Capitalization / Revenue 5.42 x 2.07 x 1.51 x 1.76 x 1.07 x 0.99 x
EV / Revenue 5.59 x 2.08 x 1.63 x 1.87 x 1.03 x 1.03 x
EV / EBITDA 19.4 x 11.7 x 9.29 x 10.3 x 6.63 x 6.69 x
EV / FCF -14.5 x 52.1 x -11.4 x 15.6 x 7.24 x -42 x
FCF Yield -6.9% 1.92% -8.8% 6.42% 13.8% -2.38%
Price to Book 3.76 x 2.87 x 1.41 x 1.26 x 0.97 x 0.84 x
Nbr of stocks (in thousands) 103,147 103,147 103,147 103,147 103,678 104,153
Reference price 2 195.4 180.0 100.8 98.70 76.95 71.25
Announcement Date 5/17/18 8/27/19 9/3/20 8/28/21 6/6/22 6/27/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 3,720 8,982 6,893 5,772 7,475 7,516
EBITDA 1 1,072 1,598 1,212 1,042 1,165 1,160
EBIT 1 871.3 1,511 1,111 894.5 1,012 986.5
Operating Margin 23.42% 16.82% 16.11% 15.5% 13.55% 13.13%
Earnings before Tax (EBT) 1 639.9 1,819 1,290 1,041 541.7 1,061
Net income 1 587.9 1,237 972.6 684.9 150.4 708.6
Net margin 15.8% 13.77% 14.11% 11.87% 2.01% 9.43%
EPS 2 5.699 11.99 9.430 6.490 1.430 6.720
Free Cash Flow 1 -1,434 359 -991.4 692 1,067 -184.6
FCF margin -38.55% 4% -14.38% 11.99% 14.27% -2.46%
FCF Conversion (EBITDA) - 22.47% - 66.38% 91.57% -
FCF Conversion (Net income) - 29.01% - 101.03% 709.37% -
Dividend per Share 2 1.000 1.000 0.5000 0.5000 0.5000 0.5000
Announcement Date 5/17/18 8/27/19 9/3/20 8/28/21 6/6/22 6/27/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 635 151 864 602 - 335
Net Cash position 1 - - - - 256 -
Leverage (Debt/EBITDA) 0.5925 x 0.0944 x 0.713 x 0.5779 x - 0.2891 x
Free Cash Flow 1 -1,434 359 -991 692 1,067 -185
ROE (net income / shareholders' equity) 5.76% 21% 13.5% 9.37% 2.76% 8.7%
ROA (Net income/ Total Assets) 5.78% 10.7% 7.18% 5.31% 5.79% 5.44%
Assets 1 10,163 11,564 13,550 12,889 2,597 13,019
Book Value Per Share 2 52.00 62.60 71.30 78.40 79.00 84.90
Cash Flow per Share 2 4.150 1.460 1.460 1.220 2.110 2.400
Capex 1 282 438 603 91.2 740 938
Capex / Sales 7.58% 4.87% 8.75% 1.58% 9.9% 12.48%
Announcement Date 5/17/18 8/27/19 9/3/20 8/28/21 6/6/22 6/27/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.98% 43.67B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.67% 22.51B
SANDOZ GROUP AG Stock Sandoz Group AG
+14.89% 14.6B
CIPLA LIMITED Stock Cipla Limited
+14.32% 13.74B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+44.72% 11.91B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.37% 7.04B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+10.21% 5.42B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BLISSGVS Stock
  4. BLISSGVS Stock
  5. Financials Bliss GVS Pharma Limited